An AllTrials project

NCT01652079: A trial that was reported late by Massachusetts General Hospital

This trial has reported, although it was 1354 days late in doing so.

Full data

Full entry on NCT01652079
Title A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer
Results Status Reported (late)
ACT or pACT? This is what FDAAA officially calls a "probable Applicable Clinical Trial"
Start date April 30, 2012
Completion date March 31, 2018
Required reporting date March 31, 2019, midnight
Actual reporting date Dec. 14, 2022
Date last checked at Oct. 23, 2023
Days late 1354